文献速递瓣膜病与结构性心脏病血脂与心血管预防

阿司匹林使用、脂蛋白(a)与钙化性主动脉瓣疾病:MESA研究

Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis.
PubMed 文献 · Eur Heart J · 2026-01-01

基于MESA前瞻性队列最多6598名参与者,评估规律阿司匹林使用与随访中新发主动脉瓣钙化及重度主动脉瓣狭窄的关联。在脂蛋白(a)升高者中,规律阿司匹林与较低的新发主动脉瓣钙化和重度主动脉瓣狭窄风险相关;但在低密度脂蛋白胆固醇升高者中未观察到关联。

要点

  • 低密度脂蛋白胆固醇升高者中未观察到阿司匹林与主动脉瓣钙化或狭窄的关联。

核心结论

  • 在脂蛋白(a)升高者中,规律阿司匹林使用与较低的新发主动脉瓣钙化和重度主动脉瓣狭窄风险相关。
  • 在低密度脂蛋白胆固醇升高者中,未观察到规律阿司匹林使用与主动脉瓣钙化或重度主动脉瓣狭窄的关联。

研究设计与样本

  • 观察性研究,纳入MESA研究中最多6598名参与者。
  • 通过非增强心脏计算机断层扫描测量主动脉瓣钙化。
  • 采用多变量Cox风险回归评估自我报告的规律阿司匹林使用(每周≥3天)与新发主动脉瓣钙化和重度主动脉瓣狭窄的关联,并按脂蛋白(a)和低密度脂蛋白胆固醇分层。

主要发现

  • 平均年龄62岁,53%为女性,23%报告规律阿司匹林使用,8%发生主动脉瓣钙化(中位8.9年),1%发生重度主动脉瓣狭窄(中位16.7年)。

临床怎么用

  • 对于脂蛋白(a)升高的患者,规律阿司匹林使用可能与较低的新发主动脉瓣钙化和重度主动脉瓣狭窄风险相关。
  • 该研究为探索性分析,尚不能据此推荐阿司匹林用于预防主动脉瓣钙化或狭窄,需确证性研究。

局限性

  • 为探索性分析,基于前瞻性观察性队列数据,不能确立因果关系。
  • 阿司匹林使用为自我报告,可能存在错分。
  • 主动脉瓣钙化和脂蛋白(a)数值未告知参与者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Lipoprotein(a) [Lp(a)] and LDL cholesterol (LDL-C) are causally linked to aortic valve calcium (AVC) and aortic stenosis (AS). Lipoprotein(a) has anti-fibrinolytic properties; therefore, aspirin may reduce cardiovascular disease risk among individuals with high Lp(a). This analysis sought to determine the association of aspirin with incident AVC and AS across Lp(a) and LDL-C levels. METHODS: This observational study included up to 6598 participants in the Multi-Ethnic Study of Atherosclerosis. Aortic valve calcium was measured on non-contrast cardiac computed tomography. Multivariable Cox hazards regression assessed the association of self-reported regular aspirin use (≥3 days/week) with incident AVC and severe AS, stratified by Lp(a) and LDL-C. Aortic valve calcium and Lp(a) values were not reported to participants. RESULTS: Mean age was 62 years, 53% were women, 23% reported regular aspirin use, 8% developed AVC (median 8.9 years), and 1% developed severe AS (median 16.7 years). Among individuals with elevated Lp(a), regular aspirin use was associated with a lower risk of incident AVC (Lp(a) ≥75 mg/dL: hazard ratio (HR) .42, 95% confidence interval (CI) .19-.93; Lp(a) ≥100 mg/dL: HR .17, 95% CI .04-.67) and severe AS (Lp(a) ≥50 mg/dL: HR .13, 95% CI: .04-.47; Lp(a) ≥75 mg/dL: HR .02, 95% CI .001-.29). For participants with elevated LDL-C, there was no association of regular aspirin use with incident AVC (LDL-C ≥130 mg/dL: HR 1.02, 95% CI .66-1.58; LDL-C ≥160 mg/dL: HR 1.51, 95% CI .53-4.28) or severe AS (LDL-C ≥100 mg/dL: HR .70, 95% CI .39-1.26; LDL-C ≥130 mg/dL: HR .46, 95% CI .14-1.47). CONCLUSIONS: In this exploratory analysis of prospective observational cohort data, regular aspirin use was associated with a lower risk of AVC and severe AS in persons with high Lp(a), but not high LDL-C. Confirmatory studies are required to determine the role of aspirin in the prevention of AVC and AS for persons with high Lp(a).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Razavi AC, Bhatia HS, Marrero N, et al. Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis. Eur Heart J. 2026. PMID: 41721439. doi:10.1093/eurheartj/ehag018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。